

11-25-2014

The emerging roles of GPRC5A in diseases.

Honglei Zhou

Computational Medicine Center, Thomas Jefferson University

Isidore Rigoutsos

Computational Medicine Center, Thomas Jefferson University

Follow this and additional works at: <https://jdc.jefferson.edu/tjucompmedctrfp>

 Part of the [Other Medical Specialties Commons](#)

[Let us know how access to this document benefits you](#)

Recommended Citation

Zhou, Honglei and Rigoutsos, Isidore, "The emerging roles of GPRC5A in diseases." (2014). *Computational Medicine Center Faculty Papers*. Paper 11.

<https://jdc.jefferson.edu/tjucompmedctrfp/11>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Computational Medicine Center Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

The emerging roles of GPRC5A in diseases

Honglei Zhou¹ and Isidore Rigoutsos¹

¹ Computational Medicine Center, Jefferson Alumni Hall, Thomas Jefferson University, Philadelphia, PA

Correspondence to: Isidore Rigoutsos, **email:** isidore.rigoutsos@jefferson.edu

Keywords: GPRC5A, RAI3, tumor suppressor, oncogene, dual-behavior, cancer

Received: November 18, 2014

Accepted: November 24, 2014

Published: November 25, 2014

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The 'Retinoic Acid-Inducible G-protein-coupled receptors' or RAIG are a group comprising the four orphan receptors GPRC5A, GPRC5B, GPRC5C and GPRC5D. As the name implies, their expression is induced by retinoic acid but beyond that very little is known about their function. In recent years, one member, GPRC5A, has been receiving increasing attention as it was shown to play important roles in human cancers. As a matter of fact, dysregulation of GPRC5A has been associated with several cancers including lung cancer, breast cancer, colorectal cancer, and pancreatic cancer. Here we review the current state of knowledge about the heterogeneity and evolution of GPRC5A, its regulation, its molecular functions, and its involvement in human disease.

INTRODUCTION

The G protein-coupled receptor, class C, group 5, member A (*GPRC5A*), also known as Retinoic acid-induced gene 3 (*RAI3*) or Retinoic acid-induced gene 1 (*RAIG1*) was first cloned in 1998 [1]. *GPRC5A* is primarily expressed in lung and lowly expressed or absent in other tissues (Figure 1A). In normal tissues the *GPRC5A* protein mainly locates at plasma membrane, perinuclear vesicle, endoplasmic reticulum, Golgi apparatus and extracellular vesicular exosomes [1-5] – see also the Human Protein Atlas at www.proteinatlas.org. Previous *GPRC5A* studies indicated that it plays important roles and that its dysregulation could result in many different types of cancer in humans (Figure 1B) as well as other diseases [5-13]. To better understand the field of *GPRC5A* research, here we summarize and discuss what is currently known about this gene and its protein.

Heterogeneity and Evolution of *GPRC5A* gene

GPRC5A is expressed in different mammals and other tetrapods as well as in birds, reptiles, amphibians, and fish [14]. Phylogenetic analysis shows that the amino acid sequence of human *GPRC5A* shares a high percentage of sequence identity with orthologues from other species, indicating that it has been conserved in evolution: 99% with *Pan troglodytes*, 76% with *Mus musculus*, 55% with

Columba livia, 52% with *Ophiophagus Hannah*, and 46% with *Xenopus laevis*. See also Figure 2A. In addition to *GPRC5A*, there are three more members in this group of receptors, each with different degrees of evolutionary conservation. Amino acid sequence alignment of the four members shows that *GPRC5A* shares 31%~42% sequence identity with the other three members [15, 16] – see also Figure 2B. The four members of group 5 receptors have high sequence identity within the transmembrane segments while the major difference occurs at N-terminus. The N-termini of *GPRC5A* and *GPRC5D* are shorter than those of *GPRC5B* and *GPRC5C*. On the other hand, both *GPRC5B* and *GPRC5C* contain highly conserved cysteines in the first and second extracellular loops (highlighted in Figure 2B), but *GPRC5A* and *GPRC5D* lack this residue [15]. In the absence of a long N-terminus, it's unlikely that *GPRC5A* can bind an agonist at its amino-terminus domain. Instead, agonists may bind to the 7 transmembrane (TM) of *GPRC5A*, *GPRC5B*, *GPRC5C* and *GPRC5D*, similarly to class A GPCRs [15, 17, 18]. Currently, no ligand is known for any of the members of RAIG. The human *GPRC5A* gene contains many Single Nucleotide Polymorphisms (SNPs) in its 5' untranslated regions (5'UTR), its coding region, and its 3'UTR (listed in Additional file 1): whether these variants have any functional impact (through post-transcriptional effects or changes in the amino acid sequence) is not currently known.

Transcriptional Regulation of *GPRC5A*

GPRC5A was first identified as a retinoic acid-induced gene and its locus contains a novel retinoic acid response element (RARE) at its proximal 5' upstream region (Figure 3) [19]. In the absence of retinoic acid, retinoic acid receptors bind to the RARE as RAR/RXR heterodimers [20, 21], recruiting co-repressor proteins and repressing *GPRC5A* gene transcription. Binding of agonist ligands to RAR/RXRs results in dissociation of co-repressor and recruitment of co-activator proteins, which in turn promotes *GPRC5A* gene transcription (Figure 4) [19, 22-26].

The *GPRC5A* gene locus also contains p53 consensus DNA binding sequences in the promoter region (Figure 3 and Figure 4) [27]. Overexpression of wild-type p53 represses *GPRC5A* expression in 2774qw1 human ovarian tumor cell line [27]. Both microarray and quantitative RT-PCR in MDA-MB-468, BT-20, BT-549,

and SK-BR-3 cells which contain mutant p53 and in T47D, MCF7, ZR-75-1, and BT474 cells which contain wild type p53 show that *GPRC5A* mRNA is up-regulated in p53 mutated cell lines [27]. Besides p53 and retinoic acid, *GPRC5A* could be regulated by cAMP as there is a cAMP-responsive element (CRE) in its promoter region and *GPRC5A*'s expression could be induced by cAMP signaling (Figure 3 and Figure 4). Interestingly, cAMP and retinoic acid might synergistically regulate *GPRC5A* expression [28]. In addition to these three regulatory elements in promoter region, the ENCODE project has identified several additional transcription factors that bind to *GPRC5A* promoter region (Figure 3 and Additional file 2 and <http://genome.ucsc.edu/>).

The *GPRC5A* gene locus contains multiple BRCA1 binding sites (Figure 3). BRCA1 could work either as an activator or as a repressor by association with different other transcription factors [13, 29-37]. A previous study showed that knockdown of BRCA1 results in down-




Figure 1: *GPRC5A* expression. A. Levels of expression of *mRNA* in different organs and tissues. *mRNA* expression is measured by using RNA-seq. The expression levels are plotted as number of Fragments Per Kilobase of Exon Per Million Fragments Mapped. B. Expression of *protein* in different organs and tissues in both normal and cancer. Protein levels are measured by using immunohistochemistry. Different intensities indicate different expression levels. The Figure was compiled using data is from The Human Protein Atlas <http://www.proteinatlas.org/>.

regulation of *GPRC5A* expression [13], suggesting that BRCA1 may work as a positive activator of *GPRC5A* expression. The locus also contains FOS and JUN binding sites (Figure 3). FOS and JUN are encoded by proto-oncogenes and bind to each other to form the Activator Protein-1 (AP-1) complex, which could in turn activate gene transcription [38-40]. AP-1 activity is usually induced by stimulations such as growth factors, pro-inflammatory cytokines and is UV-radiation-dependent on the MAPK cascade, JNK and p38 [38, 41-43]. As *GPRC5A* expression could be induced by serum in cell culture [27, 44], it is very likely that FOS and JUN binding sites within *GPRC5A* gene are functional.

Another transcription factor MYC also binds to *GPRC5A* promoter region in some cancer cells like HeLa and HepG2 cells (Figure 3), whereas not in embryonic stem (ES) cells [45]. *GPRC5A* expression level is lower in ES cells than trophoblast and overexpression of MYC in ES cells down-regulate *GPRC5A* mRNA [45].


Post-transcriptional Regulation of *GPRC5A*

MicroRNAs (miRNAs) are small non-coding RNAs that function as transcriptional and post-transcriptional

regulators of gene expression [46] and would be among the first candidates to post-transcriptionally regulate *GPRC5A*. However, very little is currently known in this regard. In a recent report, *GPRC5A* mRNA was shown to be targeted at its 5'UTR by miR-103a-3p in pancreatic cells [47]. This is a very interesting finding considering that currently only a handful of examples are known in the literature where targeting of a 5'UTR by a miRNA leads to the down-regulation of the respective mRNA (Figure 4). In this particular case, it was shown that overexpression of miR-103a-3p reduces both *GPRC5A* mRNA and protein in cells. In addition to miR-103a-3p, computational predictions (Table 1) using the *rna22* algorithm [48, 49] suggest that many other putative miRNA target sites are present along the length of *GPRC5A*'s mRNA.

Among the important post-transcriptional regulators are also RNA binding proteins (RBPs) [50] as well as long non-coding RNAs (lncRNAs) [51-54]. Both are suspected of playing roles in post-transcriptionally regulating *GPRC5A* but no data are available at this time [55-57].

A



B



Figure 2: A. Alignment of human *GPRC5A* across several species. Identical (*) and conservatively substituted (:) amino acids are indicated. Gaps are shown with “-” whereas putative TM segments are over-lined. **B.** Alignment of the four receptors from the human class C group 5. Identical (*) and conservatively substituted (:) amino acids are indicated. Gaps are shown with “-” whereas putative TM segments are over-lined.

Table 1: Number of distinct miRBase miRNAs and target sites that *rna22* predicts target *GPRC5A* (P-val ≤ 0.05).

Region	Number of targeting miRNAs (predicted)	Number of Targeting sites (predicted)
5'UTR	343	98
CDS	595	223
3'UTR	1170	922

Molecular function of *GPRC5A*

As stated above, *GPRC5A*'s short N terminus makes it unlikely that it binds ligands through that region [15]. Chimeric receptors with the N-terminus of the metabotropic glutamate receptor 1 (mGluR1) and the 7 TM region of *GPRC5A* could bind mGluR1 ligands [40], but is not activated [15]. This indicates that the signaling transduction cascade may differ in the case of *GPRC5A* from other class C GPCRs. Interestingly,

overexpression of *GPRC5A* in Nthy-ori 3-1 cells down-regulated *Gsa* expression and reduced intracellular cAMP levels compared to cells transfected with the empty vector [28]. In turn, cAMP signaling could mediate *GPRC5A* expression by cAMP-responsive element (CRE) motif close to *GPRC5A* gene's transcription initiation site [28]. The results indicate *GPRC5A* may form a feedback loop in regulating cAMP signaling.

In addition to cAMP signaling, *GPRC5A* is also involved in the NF-κB and STAT3 signaling pathways [58, 59] – see also Figure 4. Knockout of *GPRC5A* in




Figure 3: Chromosomal locus, gene architecture and transcription factor binding information. A. *GPRC5A* gene (ENSG00000013588) location is chromosome 12:13,030,138-13,084,449. B. RAR/RXR binding site, CREB binding site, TP53 binding sites, BRCA1 binding sites, FOS/JUN binding sites, and MYC binding site are located between 13,043,716 and 13,044,596. C. *GPRC5A* mRNA (ENST00000014914) is spliced from the region between 13,043,716 and 13,070,871. Transcription factor information was compiled using data from the ENCODE project predictions from JASPAR [92].

mouse lung cells inhibits *SOCS3* expression, which leads to persistent STAT3 activation under stimulation and up-regulation of STAT3-regulated cell survival genes, resulting in cell transformation and resistance to cell death [58, 60-62]. Besides, in *GPRC5A* knockout mouse lung cells, both basal NF- κ B activation and lipopolysaccharide-induced NF- κ B activation are elevated [59]. Enhanced NF- κ B activation up-regulates multiple NF- κ B target genes in cells, leading to increased inflammation [42, 59, 63].

Besides STAT3 and NF- κ B signaling pathway, *GPRC5A* is involved in regulating the cell cycle. It probably achieves this through *FEN1*, *MCM2*, *CCND1* and *UBE2C* as the expression of these genes is up-regulated following loss of *GPRC5A* expression in lung adenocarcinoma [64]. But a detailed understanding of the

regulatory mechanism is still lacking.

The *GPRC5A* protein is also post-translationally modified. For example, it is known that the amino acid residues S301 and S345 are phosphorylated during mitosis [65-68] – see also Figure 4. Phosphorylation of *GPRC5A* may play a role during cell cycle progression. Besides phosphorylation, N-linked glycosylation probably occurs at R158. Recent studies show that *GPRC5A* could also be ubiquitinated at K285, K333, K348 and K353 [69-74], but detailed mechanisms and functional roles of *GPRC5A* ubiquitination are not yet available.

GPRC5A also interacts with multiple proteins *in vivo*. Among the probable interacting partners of *GPRC5A* are EIF4A1 and HSPA9 [75]. In addition, it has been shown that *GPRC5A* is co-fractionated with




Figure 4: A systemic view of *GPRC5A*'s activity. In the nucleus, TP53 inhibits *GPRC5A* gene transcription by binding to *GPRC5A*'s promoter region. On the other hand, cAMP promotes *GPRC5A*'s transcription by binding to the latter's promoter region along with cAMP receptor protein (CRP). RA binding to RAR/RXRs results in dissociation of co-repressor and recruitment of co-activator proteins that in turn promotes *GPRC5A* gene transcription. In the cytosol, *GPRC5A* mRNA is targeted by miR-103a-3p, resulting mainly in mRNA degradation. *GPRC5A* protein is phosphorylated at S301 and S345 during mitosis by cyclin-dependent kinases. In addition, R158 in *GPRC5A* is likely glycosylated *in vivo*. Also, L285, L333, L348 and L353 at the C-terminus of *GPRC5A* might be ubiquitinated by the HRD1/Cullin-Ring E3 ligase complex. With regard to downstream signaling pathways, *GPRC5A* could promote SOCS3 and BRCA1 expression while inhibiting NF- κ B and G α expression, but details of this mechanism are lacking. *GPRC5A* may also inhibit UBE2C, FEN1, MCM2 and CCND1 expression based on previously reported indirect evidence [64]. Arrows in this diagram represent up-regulation or activation. T-joints indicate down-regulation or inhibition (direct evidence) whereas dashed T-joints indicates the available evidence is indirect. Interrupted lines indicate a connection that involves one or more intermediate pathways.

Table 2: Dysregulation of GPRC5A in different diseases.

Disease	Level Cancer vs. Normal	Methods	Reference
Oral Squamous Cell Carcinoma	↓	IHC	[10]
Non-Small Cell Lung Carcinoma	↓	Microarray; qRT-PCR;	[78, 85]
Chronic Obstructive Pulmonary Disease	↓	Microarray; qRT-PCR;	[85]
Breast Carcinoma [#]	↓	NGS;RT-PCR	[13]
Primary Myelodysplastic Syndrome	↓	Microarray	[86]
Hepatocellular Carcinoma	N/A ^(d)	Microarray	[8]
Hepatocellular Carcinoma	↓	qRT-PCR	[84]
Colorectal Adenocarcinoma	↑	LC-MS/MS	[12]
Breast Carcinoma (Primary)	↑	Microarray	[81]
Breast Carcinoma (Invasive)	↑	CPA; IHC	[82]
Colorectal Adenocarcinoma	↑	LC-MS/MS;IHC	[5]
Atherosclerosis ^(a)	↑	Microarray	[9]
Gastric Carcinoma	↑	Microarray; qRT-PCR;	[7]
Breast Carcinoma	↑	qRT-PCR	[80]
Intrahepatic Cholangiocarcinoma	↑	Microarray; qRT-PCR	[11]
Pancreatic Ductal Adenocarcinoma ^(b)	↑	Microarray	[27]
Breast Carcinoma ^(c)	↑	Microarray; qRT-PCR	[27]
Hepatocellular Carcinoma	↑	qRT-PCR; WB; IHC	[83]

^(#) *BRCA1* 5382insC mutation carriers vs. *BRCA1* wild-type patients. ^(a) The SMC cell line is analyzed in this study. ^(b) Pancreatic cell lines are analyzed in this study. ^(c) Breast cell lines are analyzed in this study. ^(d) *GPRC5A* expression level is compared within patients before treatment and after treatment. *GPRC5A* is up-regulated after treatment.

GTF2F2, MPV17, NOLC1, and SLC25A3 under certain experimental conditions. In other experiments, *GPRC5A* was shown to interact with TRIM69 or UBC [69-74, 76, 77].

***GPRC5A* and its elucidated roles in diseases**

We next review the current body of literature regarding the involvement of *GPRC5A* in various diseases (Table 2).

• *GPRC5A* and non-small cell lung carcinoma:

In non-small cell lung carcinoma (NSCLC), *GPRC5A* mRNA levels are lower than in adjacent normal tissues [78]. Ectopic overexpression of *GPRC5A* in NSCLC cell line H1792 reduces cells' growth in soft agar. In addition, homozygous *GPRC5A* knockout mice are much more prone to develop lung tumors at 1-2 years of age than heterozygous or wild type mice. But deficiency of *GPRC5A* does not cause significant developmental defects in the lungs of mice [79]. Other parallel studies have shown that knockout of *GPRC5A* in mice leads to activation of NF-κB, promoting lung inflammation and tumorigenesis, and enhances the transformed phenotype in normal and malignant lung epithelial cells through STAT3 signaling pathway [58, 59]. Studies also show that lung tumorigenesis in the *GPRC5A*-KO mouse model is augmented by nicotine-derived nitrosamine ketone (NNK) and that gene expression changes are induced by tobacco carcinogens [64].

• *GPRC5A* and oral squamous cell carcinoma:

GPRC5A expression level is very high in normal oral tissue, especially in differentiated areas whereas in oral squamous cell carcinoma (OSCC) its expression is repressed [10]. In OSCC, *GPRC5A* expression is negatively correlated to OSCC's differential level. *In vitro* experiments revealed that overexpression of *GPRC5A* in OSCC CAL27 cells suppresses the cells' anchorage-independent growth activity, indicating that *GPRC5A* plays a tumor suppressor role in oral tissue.

• *GPRC5A* and breast cancer:

The evidence so far regarding *GPRC5A*'s role in breast cancer has been conflicting. In one breast cancer study [80] it was shown that *GPRC5A* mRNA is up-regulated in 19 of 25 primary breast cancers and in 6 of 11 breast cancer cell lines examined, compared with normal mammary gland tissue. Moreover, knockdown of *GPRC5A* by small interfering RNA (siRNA) in breast cancer cell lines MCF7 and T47D suppressed cancer cells' growth [80]. Another group found that in breast cancer, the expression of *GPRC5A* along with that of *PYCARD* and *FXRD3* can serve as a good predictor of treatment outcome and enhances the predictive power of tumor size [81]. However, another study [82] reported that although *GPRC5A* expression is up-regulated in breast cancer, its expression level is not associated with tumor stage, lymph node status, histological grading or histological tumor type, or with overall and recurrence-free survival. Another recent study showed that the germline inactivating mutation c.183delG of *GPRC5A* is enriched in breast cancer patients carrying

the 5382insC allele of *BRCA1* [13]. Lastly, *in vitro* experiments revealed that *GPRC5A* is involved in forming radiation-induced *BRCA1* and *RAD51* DNA repair foci and that knockdown of *GPRC5A* attenuates DNA repair foci in cells following radiation [13].

• ***GPRC5A* and colorectal cancer:** In normal colon tissue, *GPRC5A* is expressed at low levels [1]. The majority of colon epithelium is negative or weak for *GPRC5A* expression, while only neuroendocrine cells within the colonic crypts show high expression level on plasma membrane [5]. In colorectal cancer, *GPRC5A* is abundantly present in tumor epithelium with the neuroendocrine cells showing strong staining on the plasma membrane [5]. Within neoplastic epithelium, its localization pattern is variable with most colorectal cancer tissues displaying diffuse cytoplasmic expression. Strong cytoplasmic expression of *GPRC5A* in colorectal cancer tissues is significantly associated with disease recurrence in Dukes' A-C (stage 1-3) patients when compared to low or negative expression of *GPRC5A* in cancer tissues. In another study, 33 cases of primary colorectal cancer and 16 colon polyps were subjected to LC-MS/MS analysis [12]. In these samples, *GPRC5A* level is higher in both metastatic and non-metastatic colorectal cancer than it is in polyps indicating that *GPRC5A* could be used as a biomarker in the diagnosis of colorectal cancer.

• ***GPRC5A* and gastric cancer:** In normal small intestine, *GPRC5A* is expressed at very low levels whereas in gastric cancer tissues *GPRC5A* is elevated significantly [7]. The pattern of *GPRC5A* expression in gastric cancer tissues is quite different from that of normal mucosa and of adjacent noncancerous lesion samples. This raises the possibility that *GPRC5A* can be used as a potential biomarker and a treatment target for gastric cancer based on its membrane localization and its association with cancer cell proliferation.

• ***GPRC5A* and hepatocellular carcinoma:** Based on the currently available evidence it is not clear whether in liver *GPRC5A* acts an oncogene or as tumor suppressor. In one study, it was reported that *GPRC5A* expression is higher in hepatocellular carcinoma (HCC) than in paratumor or in normal liver tissues [83]. Higher expression of *GPRC5A* is associated with lower overall and disease-free survival rate in HCC patients [83]. However, in another study researchers reported that *GPRC5A* mRNA levels are lower in seven newly established cell lines from patient derived tumor xenografts [84]. Yet another study showed that *GPRC5A* mRNA levels are higher in HCC patients after 8-week treatment with peretinoin and that the expression of 233 genes including *GPRC5A* could classify patients into one of two groups, recurrence vs. non-recurrence, with a prediction accuracy rate of 79.6% [8].

• ***GPRC5A* and other diseases:** In chronic obstructive pulmonary disease (COPD) patients, the levels of *GPRC5A* protein were significantly lower

in normal bronchial epithelia (NBE) compared with healthy controls [85]. As the levels of *GPRC5A* mRNA decrease from normal people to patients with either COPD or adenocarcinoma it is likely that in this context *GPRC5A* acts as a tumor suppressor. On the other hand, in intrahepatic cholangiocarcinoma (ICC), *GPRC5A* mRNA levels are higher than in normal tissue [11] suggesting that they could serve as a novel biomarker for classifying and diagnosing this highly fatal type of carcinoma. In myelodysplastic syndrome (MDS), *GPRC5A* mRNA levels were found to be lower in CD34+ cells, which could explain these cells' susceptibility to cell damage [86].

CONCLUSION

The *GPRC5A* gene is conserved from mammals to fish [14]. In the disease context, *GPRC5A* was originally reported as a tumor suppressor in non-small cell lung carcinoma. Later its tumor suppressor ability was also shown in oral squamous cell carcinoma. Subsequent reports indicated that in breast cancer, colorectal cancer and pancreatic cancer *GPRC5A* could also behave as an oncogene. This dual behavior makes *GPRC5A* a very interesting gene to study. Nonetheless, its likely interactions with many other factors some of which may be present in some cell types and absent in other cell types suggest that a lot more research work will be required to understand how this dual behavior arises. Recent research efforts revealed that mRNA transcripts could play additional important roles, besides their protein coding ability, by decoying miRNAs [87-91]. As the *GPRC5A*'s mRNA contains many putative miRNA-binding sites it is conceivable that some of its functional roles are effected through the decoying of one or more miRNAs. To prove this hypothesis and to elucidate the regulatory roles of *GPRC5A* mRNA and protein additional research is needed.

Not surprisingly considering that *GPRC5A* was originally identified as a retinoid acid induced molecule, *GPRC5A* contains a RAR/RXR binding site [1]. In addition, *GPRC5A*'s expression is suppressed by p53 and mutation of p53 leads to increased levels of *GPRC5A* in p53-mutant breast cancer cells [27]. Furthermore, as the *GPRC5A* locus is favored by multiple other transcription factors such as *BRCA1*, *FOS*, *JUN* and *MYC*, dysregulation of one or more of these transcription factors may lead to abnormal expression of *GPRC5A* [13, 29, 38, 45].

With respect to post-transcriptional regulation, we recently reported that miR-103a-3p can regulate *GPRC5A* protein expression by targeting the 5'UTR of *GPRC5A*'s mRNA. This finding suggests that to understand *GPRC5A*'s post-transcriptional regulation one needs to consider miRNA targets beyond its mRNA's 3'UTR. Moreover, RBPs and possibly lncRNAs might also be involved in regulating *GPRC5A*. However, no such interactions are currently known.

With respect to post-translational modification, several articles report that GPRC5A protein is phosphorylated at S301 and S345 during mitosis [65-68]. N-glycosylation and ubiquitination also occur but the physiological functions of these modifications remain unclear.

With respect to its participation in signaling pathways relatively little information is currently available. One line of work reported that *GPRC5A* expression impacts on the cAMP signaling pathway [28]. In another line of work it was shown that knocking out GPRC5A leads to the activation of the NF- κ B and STAT3 signaling pathways and results in cell proliferation and resistance to cell death [58, 59]. Additionally, loss of GPRC5A could result in up-regulation of *FEN1*, *MCM2*, *CCND1* and *UBE2C*, all of who are involved in cell cycle regulation [64]. However, it is still unknown how exactly GPRC5A interacts these pathways.

Some of the previous studies attempted to find a potential ligand for GPRC5A [15, 28, 58] but without success. In addition, it is unclear how GPRC5A is activated. As this gene is found to be dysregulated in many cancers we expect that further studies will provide additional insights about its post-transcriptional and post-translational regulation and function. In turn these findings will help advance the diagnosis and eventually the treatment of cancers through the manipulation of key stages of this protein's lifecycle.

ACKNOWLEDGEMENTS

The work was supported in part by a W. M. Keck Foundation grant (IR), a Hirshberg Foundation for Pancreatic Cancer Research award (IR), and by institutional funds.

REFERENCES

1. Cheng Y and Lotan R. Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. *The Journal of biological chemistry*. 1998; 273(52):35008-35015.
2. Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA, Kleta R, Wang NS and Knepper MA. Large-scale proteomics and phosphoproteomics of urinary exosomes. *Journal of the American Society of Nephrology : JASN*. 2009; 20(2):363-379.
3. Gonzalez-Begne M, Lu B, Han X, Hagen FK, Hand AR, Melvin JE and Yates JR. Proteomic analysis of human parotid gland exosomes by multidimensional protein identification technology (MudPIT). *Journal of proteome research*. 2009; 8(3):1304-1314.
4. Prunotto M, Farina A, Lane L, Pernin A, Schifferli J, Hochstrasser DF, Lescuyer P and Moll S. Proteomic analysis of podocyte exosome-enriched fraction from

- normal human urine. *Journal of proteomics*. 2013; 82:193-229.
5. Zougman A, Hutchins GG, Cairns DA, Verghese E, Perry SL, Jayne DG, Selby PJ and Banks RE. Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker. *European journal of cancer*. 2013; 49(2):531-539.
6. Acquafreda T, Soprano KJ and Soprano DR. GPRC5A: A potential tumor suppressor and oncogene. *Cancer biology & therapy*. 2009; 8(10):963-965.
7. Cheng L, Yang S, Yang Y, Zhang W, Xiao H, Gao H, Deng X and Zhang Q. Global gene expression and functional network analysis of gastric cancer identify extended pathway maps and GPRC5A as a potential biomarker. *Cancer letters*. 2012; 326(1):105-113.
8. Honda M, Yamashita T, Yamashita T, Arai K, Sakai Y, Sakai A, Nakamura M, Mizukoshi E and Kaneko S. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. *BMC cancer*. 2013; 13:191.
9. Karagiannis GS, Weile J, Bader GD and Minta J. Integrative pathway dissection of molecular mechanisms of moxLDL-induced vascular smooth muscle phenotype transformation. *BMC cardiovascular disorders*. 2013; 13:4.
10. Liu SL, Zhong SS, Ye DX, Chen WT, Zhang ZY and Deng J. Repression of G protein-coupled receptor family C group 5 member A is associated with pathologic differentiation grade of oral squamous cell carcinoma. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*. 2013; 42(10):761-768.
11. Subrungruanga I, Thawornkunob C, Chawalitchewinkoon-Petmitr P, Pairojkul C, Wongkham S and Petmitrb S. Gene expression profiling of intrahepatic cholangiocarcinoma. *Asian Pacific journal of cancer prevention : APJCP*. 2013; 14(1):557-563.
12. Kume H, Muraoka S, Kuga T, Adachi J, Narumi R, Watanabe S, Kuwano M, Kodera Y, Matsushita K, Fukuoka J, Masuda T, Ishihama Y, Matsubara H, Nomura F and Tomonaga T. Discovery of Colorectal Cancer Biomarker Candidates by Membrane Proteomic Analysis and Subsequent Verification using Selected Reaction Monitoring (SRM) and Tissue Microarray (TMA) Analysis. *Molecular & cellular proteomics : MCP*. 2014; 13(6):1471-1484.
13. Sokolenko AP, Bulanov DR, Iyevleva AG, Aleksakhina SN, Preobrazhenskaya EV, Ivantsov AO, Kuligina E, Mitiushkina NV, Suspitsin EN, Yanus GA, Zaitseva OA, Yatsuk OS, Togo AV, Kota P, Dixon JM, Larionov AA, et al. High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients. *International journal of cancer Journal international du cancer*. 2014; 134(10):2352-2358.
14. Kurtenbach S, Mayer C, Pelz T, Hatt H, Leese F and Neuhaus EM. Molecular evolution of a chordate specific

- family of G protein-coupled receptors. *BMC evolutionary biology*. 2011; 11:234.
15. Brauner-Osborne H, Jensen AA, Sheppard PO, Brodin B, Krogsgaard-Larsen P and O'Hara P. Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. *Biochimica et biophysica acta*. 2001; 1518(3):237-248.
 16. Brauner-Osborne H and Krogsgaard-Larsen P. Sequence and expression pattern of a novel human orphan G-protein-coupled receptor, GPRC5B, a family C receptor with a short amino-terminal domain. *Genomics*. 2000; 65(2):121-128.
 17. Dohlman HG, Thorner J, Caron MG and Lefkowitz RJ. Model systems for the study of seven-transmembrane-segment receptors. *Annual review of biochemistry*. 1991; 60:653-688.
 18. Fredriksson R, Lagerstrom MC, Lundin LG and Schiöth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. *Molecular pharmacology*. 2003; 63(6):1256-1272.
 19. Ye X, Tao Q, Wang Y, Cheng Y and Lotan R. Mechanisms underlying the induction of the putative human tumor suppressor GPRC5A by retinoic acid. *Cancer biology & therapy*. 2009; 8(10):951-962.
 20. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, De Lera AR, Lotan R, Mangelsdorf DJ and Gronemeyer H. International Union of Pharmacology. LX. Retinoic acid receptors. *Pharmacological reviews*. 2006; 58(4):712-725.
 21. Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, Rosenberger M, Lovey A, Kastner P, Grippo JF, Chambon P and et al. Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. *Proceedings of the National Academy of Sciences of the United States of America*. 1993; 90(1):30-34.
 22. Hembree JR, Agarwal C, Beard RL, Chandraratna RA and Eckert R. Retinoid X receptor-specific retinoids inhibit the ability of retinoic acid receptor-specific retinoids to increase the level of insulin-like growth factor binding protein-3 in human ectocervical epithelial cells. *Cancer research*. 1996; 56(8):1794-1799.
 23. Kizaki M, Dawson MI, Heyman R, Elster E, Morosetti R, Pakkala S, Chen DL, Ueno H, Chao W, Morikawa M, Ikeda Y, Heber D, Pfahl M and Koeffler HP. Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation *in vitro*. *Blood*. 1996; 87(5):1977-1984.
 24. Melino G, Draoui M, Bernardini S, Bellincampi L, Reichert U and Cohen P. Regulation by retinoic acid of insulin-degrading enzyme and of a related endoprotease in human neuroblastoma cell lines. *Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research*. 1996; 7(6):787-796.
 25. Meyer M, Sonntag-Buck V, Keaveney M and Stunnenberg HG. Retinoid-dependent transcription: the RAR/RXR-TBP-EIA/EIA-LA connection. *Biochemical Society symposium*. 1996; 62:97-109.
 26. Botling J, Castro DS, Oberg F, Nilsson K and Perlmann T. Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation. *The Journal of biological chemistry*. 1997; 272(14):9443-9449.
 27. Wu Q, Ding W, Mirza A, Van Arsdale T, Wei I, Bishop WR, Basso A, McClanahan T, Luo L, Kirschmeier P, Gustafson E, Hernandez M and Liu S. Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. *The Journal of biological chemistry*. 2005; 280(13):12935-12943.
 28. Hirano M, Zang L, Oka T, Ito Y, Shimada Y, Nishimura Y and Tanaka T. Novel reciprocal regulation of cAMP signaling and apoptosis by orphan G-protein-coupled receptor GPRC5A gene expression. *Biochemical and biophysical research communications*. 2006; 351(1):185-191.
 29. Mullan PB, Quinn JE and Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. *Oncogene*. 2006; 25(43):5854-5863.
 30. Houvras Y, Benezra M, Zhang H, Manfredi JJ, Weber BL and Licht JD. BRCA1 physically and functionally interacts with ATF1. *The Journal of biological chemistry*. 2000; 275(46):36230-36237.
 31. Lechner MS, Levitan I and Dressler GR. PTIP, a novel BRCT domain-containing protein interacts with Pax2 and is associated with active chromatin. *Nucleic acids research*. 2000; 28(14):2741-2751.
 32. Maor SB, Abramovitch S, Erdos MR, Brody LC and Werner H. BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. *Molecular genetics and metabolism*. 2000; 69(2):130-136.
 33. Schlegel BP, Green VJ, Ladias JA and Parvin JD. BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10alpha in activated transcription. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97(7):3148-3153.
 34. MacLachlan TK, Takimoto R and El-Deiry WS. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. *Molecular and cellular biology*. 2002; 22(12):4280-4292.
 35. Cable PL, Wilson CA, Calzone FJ, Rauscher FJ, 3rd, Scully R, Livingston DM, Li L, Blackwell CB, Futreal PA and Afshari CA. Novel consensus DNA-binding sequence for BRCA1 protein complexes. *Molecular carcinogenesis*. 2003; 38(2):85-96.
 36. Ouchi T, Lee SW, Ouchi M, Aaronson SA and Horvath CM. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97(10):5208-5213.

37. Pao GM, Janknecht R, Ruffner H, Hunter T and Verma IM. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97(3):1020-1025.
38. Shaulian E and Karin M. AP-1 in cell proliferation and survival. *Oncogene*. 2001; 20(19):2390-2400.
39. Karin M, Liu Z and Zandi E. AP-1 function and regulation. *Current opinion in cell biology*. 1997; 9(2):240-246.
40. Brauner-Osborne H, Jensen AA, Sheppard PO, O'Hara P and Krosgaard-Larsen P. The agonist-binding domain of the calcium-sensing receptor is located at the amino-terminal domain. *The Journal of biological chemistry*. 1999; 274(26):18382-18386.
41. Salvat C, Aquaviva C, Jariel-Encontre I, Ferrara P, Pariat M, Steff AM, Carillo S and Piechaczyk M. Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation *in vivo*? *Molecular biology reports*. 1999; 26(1-2):45-51.
42. Hu Y, Jin X and Snow ET. Effect of arsenic on transcription factor AP-1 and NF-kappaB DNA binding activity and related gene expression. *Toxicology letters*. 2002; 133(1):33-45.
43. Zhang W and Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. *Cell research*. 2002; 12(1):9-18.
44. Ye X and Lotan R. Potential misinterpretation of data on differential gene expression in normal and malignant cells *in vitro*. *Briefings in functional genomics & proteomics*. 2008; 7(4):322-326.
45. Ji H, Wu G, Zhan X, Nolan A, Koh C, De Marzo A, Doan HM, Fan J, Cheadle C, Fallahi M, Cleveland JL, Dang CV and Zeller KI. Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation. *PloS one*. 2011; 6(10):e26057.
46. Chen K and Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. *Nature reviews Genetics*. 2007; 8(2):93-103.
47. Zhou H and Rigoutsos I. MiR-103a-3p targets the 5' UTR of GPRC5A in pancreatic cells. *Rna*. 2014.
48. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B and Rigoutsos I. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. *Cell*. 2006; 126(6):1203-1217.
49. Loher P and Rigoutsos I. Interactive exploration of RNA22 microRNA target predictions. *Bioinformatics*. 2012; 28(24):3322-3323.
50. Dreyfuss G, Kim VN and Kataoka N. Messenger-RNA-binding proteins and the messages they carry. *Nature reviews Molecular cell biology*. 2002; 3(3):195-205.
51. Geisler S and Collier J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. *Nature reviews Molecular cell biology*. 2013; 14(11):699-712.
52. Yoon JH, Abdelmohsen K and Gorospe M. Posttranscriptional gene regulation by long noncoding RNA. *Journal of molecular biology*. 2013; 425(19):3723-3730.
53. Clark BS and Blackshaw S. Long non-coding RNA-dependent transcriptional regulation in neuronal development and disease. *Frontiers in genetics*. 2014; 5:164.
54. Krishnan J and Mishra RK. Emerging trends of long non-coding RNAs in gene activation. *The FEBS journal*. 2014; 281(1):34-45.
55. Storz G, Opdyke JA and Zhang A. Controlling mRNA stability and translation with small, noncoding RNAs. *Current opinion in microbiology*. 2004; 7(2):140-144.
56. Brennan CM and Steitz JA. HuR and mRNA stability. *Cellular and molecular life sciences : CMLS*. 2001; 58(2):266-277.
57. Mercer TR, Dinger ME and Mattick JS. Long non-coding RNAs: insights into functions. *Nature reviews Genetics*. 2009; 10(3):155-159.
58. Chen Y, Deng J, Fujimoto J, Kadara H, Men T, Lotan D and Lotan R. Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor. *Cancer research*. 2010; 70(21):8917-8926.
59. Deng J, Fujimoto J, Ye XF, Men TY, Van Pelt CS, Chen YL, Lin XF, Kadara H, Tao Q, Lotan D and Lotan R. Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. *Cancer prevention research*. 2010; 3(4):424-437.
60. Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, Wasik M, Billestrup N and Odum N. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. *Blood*. 2001; 97(4):1056-1062.
61. Niwa Y, Kanda H, Shikauchi Y, Saiura A, Matsubara K, Kitagawa T, Yamamoto J, Kubo T and Yoshikawa H. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. *Oncogene*. 2005; 24(42):6406-6417.
62. Kim G, Ouzounova M, Quraishi AA, Davis A, Tawakkol N, Clouthier SG, Malik F, Paulson AK, D'Angelo RC, Korkaya S, Baker TL, Esen ES, Prat A, Liu S, Kleer CG, Thomas DG, et al. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model. *Oncogene*. 2014.
63. Saile B, Matthes N, El Armouche H, Neubauer K and Ramadori G. The bcl, NFkappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells. *European journal of cell biology*. 2001; 80(8):554-561.

64. Fujimoto J, Kadara H, Men T, van Pelt C, Lotan D and Lotan R. Comparative functional genomics analysis of NNK tobacco-carcinogen induced lung adenocarcinoma development in Gprc5a-knockout mice. *PloS one*. 2010; 5(7):e11847.
65. Oppermann FS, Grundner-Culemann K, Kumar C, Gruss OJ, Jallepalli PV and Daub H. Combination of chemical genetics and phosphoproteomics for kinase signaling analysis enables confident identification of cellular downstream targets. *Molecular & cellular proteomics : MCP*. 2012; 11(4):O111 012351.
66. Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, Brunak S and Mann M. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. *Science signaling*. 2010; 3(104):ra3.
67. Shiromizu T, Adachi J, Watanabe S, Murakami T, Kuga T, Muraoka S and Tomonaga T. Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. *Journal of proteome research*. 2013; 12(6):2414-2421.
68. Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ and Gygi SP. A quantitative atlas of mitotic phosphorylation. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105(31):10762-10767.
69. Wagner SA, Beli P, Weinert BT, Nielsen ML, Cox J, Mann M and Choudhary C. A proteome-wide, quantitative survey of *in vivo* ubiquitylation sites reveals widespread regulatory roles. *Molecular & cellular proteomics : MCP*. 2011; 10(10):M111 013284.
70. Lee KA, Hammerle LP, Andrews PS, Stokes MP, Mustelin T, Silva JC, Black RA and Doedens JR. Ubiquitin ligase substrate identification through quantitative proteomics at both the protein and peptide levels. *The Journal of biological chemistry*. 2011; 286(48):41530-41538.
71. Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A, Sowa ME, Rad R, Rush J, Comb MJ, Harper JW and Gygi SP. Systematic and quantitative assessment of the ubiquitin-modified proteome. *Molecular cell*. 2011; 44(2):325-340.
72. Danielsen JM, Sylvestersen KB, Bekker-Jensen S, Szklarczyk D, Poulsen JW, Horn H, Jensen LJ, Mailand N and Nielsen ML. Mass spectrometric analysis of lysine ubiquitylation reveals promiscuity at site level. *Molecular & cellular proteomics : MCP*. 2011; 10(3):M110 003590.
73. Emanuele MJ, Elia AE, Xu Q, Thoma CR, Izhar L, Leng Y, Guo A, Chen YN, Rush J, Hsu PW, Yen HC and Elledge SJ. Global identification of modular cullin-RING ligase substrates. *Cell*. 2011; 147(2):459-474.
74. Povlsen LK, Beli P, Wagner SA, Poulsen SL, Sylvestersen KB, Poulsen JW, Nielsen ML, Bekker-Jensen S, Mailand N and Choudhary C. Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. *Nature cell biology*. 2012; 14(10):1089-1098.
75. Havugimana PC, Hart GT, Nepusz T, Yang H, Turinsky AL, Li Z, Wang PI, Boutz DR, Fong V, Phanse S, Babu M, Craig SA, Hu P, Wan C, Vlasblom J, Dar VU, et al. A census of human soluble protein complexes. *Cell*. 2012; 150(5):1068-1081.
76. Hutchins JR, Toyoda Y, Hegemann B, Poser I, Heriche JK, Sykora MM, Augsburg M, Hudecz O, Buschhorn BA, Bulkescher J, Conrad C, Comartin D, Schleiffer A, Sarov M, Pozniakovsky A, Slabicki MM, et al. Systematic analysis of human protein complexes identifies chromosome segregation proteins. *Science*. 2010; 328(5978):593-599.
77. Meierhofer D, Wang X, Huang L and Kaiser P. Quantitative analysis of global ubiquitination in HeLa cells by mass spectrometry. *Journal of proteome research*. 2008; 7(10):4566-4576.
78. Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, Lotan D and Lotan R. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. *Journal of the National Cancer Institute*. 2007; 99(22):1668-1682.
79. Xu J, Tian J and Shapiro SD. Normal lung development in RAI1-deficient mice despite unique lung epithelium-specific expression. *American journal of respiratory cell and molecular biology*. 2005; 32(5):381-387.
80. Nagahata T, Sato T, Tomura A, Onda M, Nishikawa K and Emi M. Identification of RAI3 as a therapeutic target for breast cancer. *Endocrine-related cancer*. 2005; 12(1):65-73.
81. Dairkee SH, Sayeed A, Luciani G, Champion S, Meng Z, Jakkula LR, Feiler HS, Gray JW and Moore DH. Imutable functional attributes of histologic grade revealed by context-independent gene expression in primary breast cancer cells. *Cancer research*. 2009; 69(19):7826-7834.
82. Jorissen H, Bektas N, Dahl E, Hartmann A, ten Haaf A, Di Fiore S, Kiefer H, Thess A, Barth S and Klockenbring T. Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer. *BMC cancer*. 2009; 9:200.
83. Zheng J, Guo X, Gao X, Liu H, Tu Y and Zhang Y. Overexpression of retinoic acid-induced protein 3 predicts poor prognosis for hepatocellular carcinoma. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico*. 2014; 16(1):57-63.
84. Xin H, Wang K, Hu G, Xie F, Ouyang K, Tang X, Wang M, Wen D, Zhu Y and Qin X. Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts. *PloS one*. 2014; 9(1):e85308.
85. Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, Lee JJ, Solis LM, Kim ES, Kalhor N, Moran C, Sharafkhaneh A, Lotan R and Wistuba, II. G-protein coupled receptor family C, group 5, member A (GPC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive

pulmonary disease and non-small-cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2012; 7(12):1747-1754.

86. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsmann W and Koefler HP. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. *Blood*. 2002; 100(10):3553-3560.
87. Ling S, Birnbaum Y, Nanhwan MK, Thomas B, Bajaj M and Ye Y. MicroRNA-dependent cross-talk between VEGF and HIF1alpha in the diabetic retina. *Cellular signalling*. 2013; 25(12):2840-2847.
88. de Giorgio A, Krell J, Harding V, Stebbing J and Castellano L. Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN. *Molecular and cellular biology*. 2013; 33(20):3976-3982.
89. Ala U, Karreth FA, Bosia C, Pagnani A, Taulli R, Leopold V, Tay Y, Provero P, Zecchina R and Pandolfi PP. Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. *Proceedings of the National Academy of Sciences of the United States of America*. 2013; 110(18):7154-7159.
90. Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, Lieberman J, Rigoutsos I and Pandolfi PP. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. *Cell*. 2011; 147(2):344-357.
91. Rigoutsos I and Furnari F. Gene-expression forum: Decoy for microRNAs. *Nature*. 2010; 465(7301):1016-1017.
92. Mathelier A, Zhao X, Zhang AW, Parey F, Worsley-Hunt R, Arenillas DJ, Buchman S, Chen CY, Chou A, Ienasescu H, Lim J, Shyr C, Tan G, Zhou M, Lenhard B, Sandelin A, et al. JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. *Nucleic acids research*. 2014; 42(Database issue):D142-147.